

# Luca Antonioli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7775337/publications.pdf>

Version: 2024-02-01

148  
papers

6,117  
citations

87888

38  
h-index

82547

72  
g-index

149  
all docs

149  
docs citations

149  
times ranked

9239  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adenosine and inflammation: it's time to (re)solve the problem. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 43-55.	8.7	18
2	Enteric Î±-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinsonâ€™s disease before brain pathology. <i>Npj Parkinson's Disease</i> , 2022, 8, 9.	5.3	36
3	Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis. <i>Inflammation</i> , 2022, 45, 1829-1847.	3.8	11
4	Cathepsin D interacts with adenosine A2A receptors in mouse macrophages to modulate cell surface localization and inflammatory signaling. <i>Journal of Biological Chemistry</i> , 2022, 298, 101888.	3.4	4
5	Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. <i>Digestive and Liver Disease</i> , 2022, 54, 1367-1373.	0.9	10
6	May be adenosine an immuno-quorum-sensing signal?. <i>Purinergic Signalling</i> , 2022, 18, 205-209.	2.2	0
7	Adenosine Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1270, 145-167.	1.6	18
8	NLRP3 inflammasome in cardiovascular diseases: Pathophysiological and pharmacological implications. <i>Medicinal Research Reviews</i> , 2021, 41, 1890-1926.	10.5	28
9	Oral Sucrosomial Iron Is as Effective as Intravenous Ferric Carboxy-Maltose in Treating Anemia in Patients with Ulcerative Colitis. <i>Nutrients</i> , 2021, 13, 608.	4.1	12
10	DONEPEZIL IMPROVES VASCULAR FUNCTION IN A MOUSE MODEL OF ALZHEIMER'S DISEASE. <i>Journal of Hypertension</i> , 2021, 39, e21.	0.5	0
11	The role of P2Y receptors in regulating immunity and metabolism. <i>Biochemical Pharmacology</i> , 2021, 187, 114419.	4.4	22
12	Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6325.	4.1	5
13	NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodelling in a mouse model of dietâ€™induced obesity. <i>British Journal of Pharmacology</i> , 2021, 178, 3924-3942.	5.4	9
14	An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, , 1-10.	3.0	4
15	Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimerâ€™s Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 748021.	3.5	13
16	Donepezil improves vascular function in a mouse model of Alzheimerâ€™s disease. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00871.	2.4	4
17	From the intestinal mucosal barrier to the enteric neuromuscular compartment: an integrated overview on the morphological changes in Parkinsonâ€™s disease. <i>European Journal of Histochemistry</i> , 2021, 65, .	1.5	6
18	Editorial: Neurological, Metabolic and Inflammatory Disorders: A Common Root in Inflammasome. <i>Frontiers in Pharmacology</i> , 2021, 12, 808400.	3.5	0

#	ARTICLE	IF	CITATIONS
19	“Cecal Resection with Bipolar Sealing in a Rat Model”: A Promising Approach for Future Human Studies. <i>Journal of Investigative Surgery</i> , 2020, 33, 67-68.	1.3	2
20	Higher Body Mass Index and Black Race Increase Risk of Rhabdomyolysis and Acute Kidney Injury After Trauma. <i>Journal of Investigative Surgery</i> , 2020, 33, 291-292.	1.3	0
21	Protective effects of the combination <i>Bifidobacterium longum</i> plus lactoferrin against NSAID-induced enteropathy. <i>Nutrition</i> , 2020, 70, 110583.	2.4	16
22	Colonic dysmotility and inflammation associated with high fat diet-induced obesity: role of the enteric glia. <i>Proceedings of the Nutrition Society</i> , 2020, 79, .	1.0	0
23	P454 Serum oncostatin M predicts mucosal healing in Crohn’s disease patients treated with infliximab. <i>Journal of Crohn’s and Colitis</i> , 2020, 14, S406-S406.	1.3	0
24	Enteric Glia at the Crossroads between Intestinal Immune System and Epithelial Barrier: Implications for Parkinson Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9199.	4.1	35
25	Deepening the Mechanisms of Visceral Pain Persistence: An Evaluation of the Gut-Spinal Cord Relationship. <i>Cells</i> , 2020, 9, 1772.	4.1	22
26	Inflammatory Bowel Diseases: It’s Time for the Adenosine System. <i>Frontiers in Immunology</i> , 2020, 11, 1310.	4.8	7
27	The Adenosine System at the Crossroads of Intestinal Inflammation and Neoplasia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5089.	4.1	16
28	Tu1241 SERUM ONCOSTATIN M PREDICTS MUCOSAL HEALING IN CROHN’S DISEASE PATIENTS TREATED WITH INFLIXIMAB. <i>Gastroenterology</i> , 2020, 158, S-1030.	1.3	0
29	Letter: ustekinumab’s effectiveness outcomes compared with vedolizumab in Crohn’s disease—what about mucosal healing and biomarkers?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 751-752.	3.7	1
30	T04.01.20 SERUM ONCOSTATIN M PREDICTS MUCOSAL HEALING IN CROHN’S DISEASE PATIENTS TREATED WITH INFLIXIMAB. <i>Digestive and Liver Disease</i> , 2020, 52, S125-S126.	0.9	0
31	Prodromal Intestinal Events in Alzheimer’s Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3523.	4.1	24
32	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1323.	2.4	20
33	NKG2A and COVID-19: another brick in the wall. <i>Cellular and Molecular Immunology</i> , 2020, 17, 672-674.	10.5	72
34	Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?. <i>Progress in Neurobiology</i> , 2020, 191, 101806.	5.7	87
35	Serum oncostatin M at baseline predicts mucosal healing in Crohn’s disease patients treated with infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 284-291.	3.7	41
36	Approaches for designing and discovering purinergic drugs for gastrointestinal diseases. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 687-703.	5.0	9

#	ARTICLE	IF	CITATIONS
37	Role of proteinase-activated receptors 1 and 2 in nonsteroidal anti-inflammatory drug enteropathy. <i>Pharmacological Reports</i> , 2020, 72, 1347-1357.	3.3	4
38	The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis. <i>Cells</i> , 2020, 9, 1509.	4.1	13
39	Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches. <i>Trends in Molecular Medicine</i> , 2020, 26, 1021-1033.	6.7	16
40	Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1296-1305.	2.4	30
41	Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration. <i>Neurobiology of Disease</i> , 2020, 139, 104821.	4.4	28
42	Colonic dysmotility associated with high-fat diet-induced obesity: Role of enteric glia. <i>FASEB Journal</i> , 2020, 34, 5512-5524.	0.5	31
43	Differential Impact of Weight Loss and Glycemic Control on Inflammasome Signaling. <i>Obesity</i> , 2020, 28, 609-615.	3.0	17
44	Editorial: IBD Management—Novel Targets and Therapeutic Perspectives. <i>Frontiers in Pharmacology</i> , 2020, 11, 448.	3.5	2
45	Managing Obesity and Related Comorbidities: A Potential Pharmacological Target in the Adenosine System?. <i>Frontiers in Pharmacology</i> , 2020, 11, 621955.	3.5	7
46	Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 65, 298-308.	2.2	10
47	Glial A2B Adenosine Receptors Modulate Abnormal Tachykinergic Responses and Prevent Enteric Inflammation Associated with High Fat Diet-Induced Obesity. <i>Cells</i> , 2020, 9, 1245.	4.1	20
48	Intestinal epithelial barrier and neuromuscular compartment in health and disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 1564-1597.	3.3	28
49	Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1082-1082.	3.7	0
50	Interplay between colonic inflammation and tachykinergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity. <i>International Journal of Obesity</i> , 2019, 43, 331-343.	3.4	27
51	Inflammation and Vascular Ageing: From Telomeres to Novel Emerging Mechanisms. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 321-329.	2.2	17
52	High Levels of $\alpha$ -Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 1-16.	4.0	18
53	Caffeine and Bones: If Less Is Good, More May Not Be Better. <i>Journal of Caffeine and Adenosine Research</i> , 2019, 9, 38-39.	0.6	1
54	Sa1311—Anti-Inflammatory and Visceral Pain Relieving Effects of Ar170, a Potent and Selective A3 Receptor Agonist, in a rat Model of Colitis. <i>Gastroenterology</i> , 2019, 156, S-313.	1.3	0

#	ARTICLE	IF	CITATIONS
55	1087 " Enteric Inflammation and Altered Colonic Cholinergic Neurotransmission in a Spontaneous Model of Alzheimer's Disease:Timing from Early Phases to Full Disease Development. <i>Gastroenterology</i> , 2019, 156, S-230.	1.3	0
56	P709 Early measurement of serum cytokines as predictor of clinical and endoscopic outcome to vedolizumab in patients with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S475-S475.	1.3	0
57	Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2876.	4.1	67
58	The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases. <i>Pharmacological Reviews</i> , 2019, 71, 345-382.	16.0	115
59	Su1903 " Early Measurement of Serum Cytokines As Predictor of Clinical and Endoscopic Outcome to Vedolizumab in Patients with Ulcerative Colitis. <i>Gastroenterology</i> , 2019, 156, S-654.	1.3	1
60	P.07.3 EARLY MEASUREMENT OF SERUM CYTOKINES AS PREDICTOR OF CLINICAL AND ENDOSCOPIC OUTCOME TO VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS. <i>Digestive and Liver Disease</i> , 2019, 51, e222-e223.	0.9	0
61	1084 " Enteric Alpha-Synuclein Inclusions, Colonic Inflammation, Increased Mucosal Permeability and Alterations of Bowel Neuromuscular Functions Precede Central Neurodegeneration in a Transgenic Mouse Model of Parkinson's Disease. <i>Gastroenterology</i> , 2019, 156, S-229.	1.3	0
62	P2X4 receptors, immunity, and sepsis. <i>Current Opinion in Pharmacology</i> , 2019, 47, 65-74.	3.5	24
63	Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. <i>Translational Neurodegeneration</i> , 2019, 8, 5.	8.0	54
64	Rethinking Communication in the Immune System: The Quorum Sensing Concept. <i>Trends in Immunology</i> , 2019, 40, 88-97.	6.8	33
65	Risankizumab for the treatment of moderate to severe psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1-8.	3.1	8
66	Transanal Minimally Invasive Surgery: A Promising Alternative for Certain Advanced Rectal Cancer Patients. <i>Journal of Investigative Surgery</i> , 2019, 32, 377-378.	1.3	1
67	Adenosine signaling and the immune system: When a lot could be too much. <i>Immunology Letters</i> , 2019, 205, 9-15.	2.5	130
68	P060 Post-inflammatory visceral pain induced by DNBS: Preclinical features for novel therapeutics. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S123-S123.	1.3	3
69	Adenosine metabolism, immunity and joint health. <i>Biochemical Pharmacology</i> , 2018, 151, 307-313.	4.4	54
70	Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis. <i>Purinergic Signalling</i> , 2018, 14, 27-36.	2.2	19
71	Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention. <i>Frontiers in Pharmacology</i> , 2018, 9, 1340.	3.5	35
72	A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. <i>Frontiers in Pharmacology</i> , 2018, 9, 1405.	3.5	33

#	ARTICLE	IF	CITATIONS
73	The ecto-enzymes CD73 and adenosine deaminase modulate 5â€²-AMP-derived adenosine in myofibroblasts of the rat small intestine. <i>Purinergic Signalling</i> , 2018, 14, 409-421.	2.2	11
74	Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity. <i>Frontiers in Pharmacology</i> , 2018, 9, 1094.	3.5	46
75	Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?. <i>Acta Neuropathologica</i> , 2018, 136, 345-361.	7.7	167
76	Neuronal regulation of intestinal immune functions in health and disease. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13406.	3.0	15
77	Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases. <i>Frontiers in Pharmacology</i> , 2018, 9, 212.	3.5	15
78	Adenosine Regulation of the Immune System. , 2018, , 499-514.		6
79	Quorum sensing in the immune system. <i>Nature Reviews Immunology</i> , 2018, 18, 537-538.	22.7	26
80	The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity. <i>PLoS ONE</i> , 2018, 13, e0195502.	2.5	47
81	Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review. <i>Nutrition Research Reviews</i> , 2018, 31, 239-247.	4.1	40
82	The flavonoid compound luteolin prevents endothelial dysfunction in a mouse model of high fat diet-induced obesity. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-2-47.	0.0	0
83	FA-5, a novel AMP-activated protein kinase (AMPK) activator, as a new pharmacological tool for the management of bowel inflammation. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-5-2.	0.0	0
84	Rifaximin prevents diclofenac-induced enteropathy in rats through antibacterial and anti-inflammatory activities. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO3-5-28.	0.0	0
85	What's new in emergencies, trauma, and shock? Using abdominal computed tomography in geriatric patients on warfarin. <i>Journal of Emergencies, Trauma and Shock</i> , 2018, 11, 71.	0.7	1
86	A comparative study on the efficacy of NLRP3 inflammasome signaling inhibitors in a pre-clinical model of bowel inflammation. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO2-6-29.	0.0	0
87	Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3656-3671.	6.4	131
88	Colonic Dysmotility Associated with High Fat Diet-Induced Obesity: Role of the Enteric Glia. <i>Gastroenterology</i> , 2017, 152, S180.	1.3	1
89	Protective Role of Flavonoids Against Colonic Motor Dysfunctions Associated with High Fat Diet-Induced Obesity. <i>Gastroenterology</i> , 2017, 152, S828.	1.3	0
90	Enteric Protective Effects of the Combination Bifidobacterium Longum and Lactoferrin in a Rat Model of Diclofenac-Induced Intestinal Injury. <i>Gastroenterology</i> , 2017, 152, S415.	1.3	0

#	ARTICLE	IF	CITATIONS
91	Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Neuropharmacology</i> , 2017, 123, 22-33.	4.1	15
92	A Purinergic Trail for Metastases. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 277-290.	8.7	28
93	Hypoxia-inducible-factor-1 in trauma and critical care. <i>Journal of Critical Care</i> , 2017, 42, 207-212.	2.2	23
94	Effects of L-DOPA/Benserazide Co-Treatment on Colonic Dysmotility and Enteric Inflammation Following Dopaminergic Nigrostriatal Neurodegeneration. <i>Gastroenterology</i> , 2017, 152, S179-S180.	1.3	0
95	A 2A adenosine receptors control pancreatic dysfunction in high-fat diet-induced obesity. <i>FASEB Journal</i> , 2017, 31, 4985-4997.	0.5	30
96	Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors. <i>Purinergic Signalling</i> , 2017, 13, 497-510.	2.2	30
97	Mechanisms Underlying the Non-Anticoagulant Effects of Apixaban and Dabigatran on the Integrity of Intestinal Mucosa: A Comparative Pre-Clinical Study. <i>Gastroenterology</i> , 2017, 152, S414-S415.	1.3	0
98	Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. <i>Drug Discovery Today</i> , 2017, 22, 1686-1696.	6.4	66
99	The Impact of Gender on Complications and Outcomes of Pelvic Fracture. <i>American Surgeon</i> , 2017, 83, 106-109.	0.8	1
100	Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles. <i>Cureus</i> , 2017, 9, e1177.	0.5	86
101	Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation. <i>Frontiers in Immunology</i> , 2017, 8, 36.	4.8	151
102	Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche. <i>Frontiers in Immunology</i> , 2017, 8, 305.	4.8	52
103	Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models. <i>Neurogastroenterology and Motility</i> , 2016, 28, 1781-1791.	3.0	41
104	Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1216292.	4.6	42
105	Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. <i>Journal of Neuroinflammation</i> , 2016, 13, 146.	7.2	77
106	Tu1889 Targeting of NLRP3 Inflammasome With a Novel Selective Inhibitor as a Suitable Strategy for the Pharmacological Treatment of Bowel Inflammation. <i>Gastroenterology</i> , 2016, 150, S968-S969.	1.3	3
107	Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects. <i>Drug Safety</i> , 2016, 39, 903-924.	3.2	25
108	Myeloid cells in the tumor microenvironment: Role of adenosine. <i>Oncolmmunology</i> , 2016, 5, e1108515.	4.6	45

#	ARTICLE	IF	CITATIONS
109	Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities. <i>Trends in Cancer</i> , 2016, 2, 95-109.	7.4	177
110	Enteric Dysfunctions in Experimental Parkinsons Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 233-243.	2.5	49
111	Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. <i>Pharmacological Research</i> , 2016, 104, 186-196.	7.1	30
112	The AMPK enzyme-complex: from the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 179-191.	3.4	41
113	Allopurinol adherence among patients with gout: an Italian general practice database study. <i>International Journal of Clinical Practice</i> , 2015, 69, 757-765.	1.7	31
114	Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon. <i>PLoS ONE</i> , 2015, 10, e0144630.	2.5	96
115	Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing. <i>FASEB Journal</i> , 2015, 29, 3626-3637.	0.5	106
116	Adenosine signalling in diabetes mellitusâ€”pathophysiology and therapeutic considerations. <i>Nature Reviews Endocrinology</i> , 2015, 11, 228-241.	9.6	133
117	An integrated assessment of histopathological changes of the enteric neuromuscular compartment in experimental colitis. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 485-500.	3.6	29
118	Comment on â€œHigh expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinomaâ€. <i>Tumor Biology</i> , 2015, 36, 7397-7398.	1.8	1
119	Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1407-1414.	2.2	56
120	Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2015, 38, 869-888.	3.2	15
121	Enteric purinergic signaling: Shaping the â€œbrain in the gutâ€. <i>Neuropharmacology</i> , 2015, 95, 477-478.	4.1	4
122	Involvement of the P2X7 Purinergic Receptor in Colonic Motor Dysfunction Associated with Bowel Inflammation in Rats. <i>PLoS ONE</i> , 2014, 9, e116253.	2.5	41
123	Role of the $A_{2B}$ receptorâ€”adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats. <i>British Journal of Pharmacology</i> , 2014, 171, 1314-1329.	5.4	26
124	Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease. <i>British Journal of Pharmacology</i> , 2014, 171, 3728-3740.	5.4	10
125	Adenosine and inflammation: what's new on the horizon?. <i>Drug Discovery Today</i> , 2014, 19, 1051-1068.	6.4	139
126	Adenosine pathway and cancer: where do we go from here?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 973-977.	3.4	16



#	ARTICLE	IF	CITATIONS
127	NSAID-Induced Enteropathy: Are the Currently Available Selective COX-2 Inhibitors All the Same?. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 348, 86-95.	2.5	44
128	Quality of Adverse Drug Reaction (QADRA) reports: an algorithm to appraise the efficiency of spontaneous reporting systems in pharmacovigilance. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2013, 21, 365-372.	1.6	4
129	The role of purinergic pathways in the pathophysiology of gut diseases: Pharmacological modulation and potential therapeutic applications. , 2013, 139, 157-188.		60
130	Immunity, inflammation and cancer: a leading role for adenosine. <i>Nature Reviews Cancer</i> , 2013, 13, 842-857.	28.4	612
131	CD39 and CD73 in immunity and inflammation. <i>Trends in Molecular Medicine</i> , 2013, 19, 355-367.	6.7	914
132	Influence of the Serotonin Transporter 5HTTLPR Polymorphism on Symptom Severity in Irritable Bowel Syndrome. <i>PLoS ONE</i> , 2013, 8, e54831.	2.5	37
133	Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders. <i>Current Drug Targets</i> , 2012, 13, 842-862.	2.1	128
134	Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms. <i>Pharmacological Research</i> , 2011, 63, 59-67.	7.1	34
135	A holistic view of adenosine in the control of intestinal neuromuscular functions: the enteric "purinome" concept. <i>British Journal of Pharmacology</i> , 2011, 164, 1577-1579.	5.4	10
136	Differential recruitment of high affinity A1 and A2A adenosine receptors in the control of colonic neuromuscular function in experimental colitis. <i>European Journal of Pharmacology</i> , 2011, 650, 639-649.	3.5	41
137	Pharmacological modulation of adenosine receptor pathways and inflammatory disorders: the way towards novel therapeutics?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 717-721.	4.1	4
138	Control of enteric neuromuscular functions by purinergic A <sub>3</sub> receptors in normal rat distal colon and experimental bowel inflammation. <i>British Journal of Pharmacology</i> , 2010, 161, 856-871.	5.4	29
139	The Blockade of Adenosine Deaminase Ameliorates Chronic Experimental Colitis through the Recruitment of Adenosine A <sub>2A</sub> and A <sub>3</sub> Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 434-442.	2.5	47
140	Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: A review. <i>Clinical Therapeutics</i> , 2009, 31, 1426-1453.	2.5	92
141	Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one Ring System as a Useful Template To Obtain Potent Adenosine Deaminase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1681-1692.	6.4	44
142	Pharmacological modulation of adenosine system: Novel options for treatment of inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 566-574.	1.9	57
143	Regulation of enteric functions by adenosine: Pathophysiological and pharmacological implications. , 2008, 120, 233-253.		103
144	Cyclooxygenase-1 Is Involved in Endothelial Dysfunction of Mesenteric Small Arteries From Angiotensin II-Infused Mice. <i>Hypertension</i> , 2007, 49, 679-686.	2.7	66

#	ARTICLE	IF	CITATIONS
145	Inhibition of Adenosine Deaminase Attenuates Inflammation in Experimental Colitis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 435-442.	2.5	96
146	Tolerability Profiles of Leukotriene Receptor Antagonists and Long-Acting $\beta_2$ -Adrenoceptor Agonists in Combination with Inhaled Corticosteroids for Treatment of Asthma: A Review. <i>Journal of Asthma</i> , 2007, 44, 411-422.	1.7	3
147	A2a receptors mediate inhibitory effects of adenosine on colonic motility in the presence of experimental colitis. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 117-122.	1.9	39
148	Differential Role of Cyclooxygenase 1 and 2 Isoforms in the Modulation of Colonic Neuromuscular Function in Experimental Inflammation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 938-945.	2.5	34